Charles River Laboratories Reports Increase in Sales despite Softening Customer Spending

Avatar

By Will Feuer

Charles River Laboratories, a contract pharmaceutical research company, has reported a rise in sales in the third quarter, even as customer spending declined.

The company’s third-quarter earnings stood at $87.4 million, or $1.69 per share, compared to $96.5 million, or $1.88 per share, during the same period last year.

Adjusted earnings, excluding one-time items, were recorded at $2.72 per share, surpassing analysts’ expectations of $2.36 per share.

Revenue experienced an almost 4% increase to reach $1.03 billion, exceeding analysts’ projections of $1.0 billion.

While Chief Executive James Foster acknowledged a decline in customer spending, he noted that there are indications of more favorable demand trends emerging.

To align with weaker demand, Charles River is implementing cost-cutting measures. The company’s profit was impacted by costs related to site-consolidation and other non-operating expenses.

The research models and services unit witnessed a revenue growth of approximately 4%, while the discovery and safety assessment unit reported a 7% increase in revenue. However, the manufacturing solutions segment experienced a decline of 7% in revenue.

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

LL Flooring Holdings Reports Widening Loss and Declining Sales in Q3

Next Post

Reynolds Consumer Products Reports Higher Earnings in Q3

Related Posts

Keep It Flowing

Times of India’s Edit Page team comprises senior journalists with wide-ranging interests who debate and opine on the…
Avatar
Read More